WuXi PharmaTech begins construction of new R￡tD and cGMP manufacturing campus in Changzhou

摘要

Syn-The-AII (STA) Pharmaceuticals Co., Ltd, a manufacturing subsidiary of WuXi PharmaTech Inc., a leading pharmaceutical, biotechnology, and medical device research and development (R￡tD) services company with operations in China and the United States, has begun construction of a new, fully integrated REtD and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai. The new construction aims to meet the rapidly growing demand for WuXi's manufacturing services, which have quadrupled their revenues in the past four years.